Evoke Pharma, Inc. - Common Stock (EVOK)
Frequently Asked Questions About Evoke Pharma, Inc. - Common Stock (EVOK)
Are there any side effects associated with Gimoti?
As with any medication, Gimoti may cause side effects. Common side effects include drowsiness, fatigue, and gastrointestinal discomfort. It's crucial for patients to discuss potential risks with their healthcare providers before starting the treatment.
Does Evoke Pharma have any partnerships or collaborations?
Evoke Pharma has actively sought collaborations to enhance its clinical development and commercialization efforts. While specific partnerships may evolve, the company continually looks for opportunities to expand its reach and resources in the pharmaceutical market.
Has Evoke Pharma conducted any clinical trials?
Yes, Evoke Pharma has conducted multiple clinical trials to evaluate the safety and efficacy of Gimoti. These trials have been critical in demonstrating the product's benefits and obtaining FDA approval.
How can investors keep track of Evoke Pharma's performance?
Investors can keep track of Evoke Pharma's performance by following its stock price on financial news platforms, reviewing its quarterly and annual reports, and monitoring press releases for updates on product development, clinical trial results, and any significant corporate announcements.
How does Evoke Pharma fund its operations?
Evoke Pharma funds its operations through a combination of equity financing, collaborations, and grants. The company has pursued various funding strategies to support its R&D efforts and to bring Gimoti to market successfully.
How does Gimoti work?
Gimoti works by acting as a dopaminergic antagonist that increases gastrointestinal motor activity. By facilitating gastric emptying, it helps alleviate symptoms of nausea, vomiting, and abdominal discomfort associated with diabetic gastroparesis.
How many employees does Evoke Pharma have?
As of the latest reports, Evoke Pharma has a small team of dedicated professionals that includes scientists, regulatory experts, and sales personnel. The company continues to grow as it advances its product pipeline and commercializes its lead candidate, Gimoti.
Is Gimoti FDA approved?
Yes, Gimoti received approval from the U.S. Food and Drug Administration (FDA) in March 2020. This approval marked a significant milestone for Evoke Pharma, making it the first nasal spray formulation of metoclopramide approved for use in the United States.
What are the challenges faced by Evoke Pharma?
Like many small biotechnology firms, Evoke Pharma faces challenges such as navigating regulatory hurdles, ensuring the commercial viability of its products, and securing funding for research and development. Additionally, competition in the pharmaceutical space is a constant concern.
What are the main goals of Evoke Pharma?
Evoke Pharma aims to develop and commercialize innovative therapies that address significant unmet medical needs, particularly in the area of gastrointestinal disorders. Their focus on novel formulations, like Gimoti, highlights their commitment to improving patient care and treatment options.
What does Evoke Pharma, Inc. do?
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal conditions. Their primary product candidate is Gimoti, a nasal spray formulation of metoclopramide, designed to treat acute and recurrent diabetic gastroparesis in women.
What is Gimoti?
Gimoti is Evoke Pharma's lead product candidate, which is a nasal spray formulation of metoclopramide. It is specifically developed for the treatment of diabetic gastroparesis, a condition often characterized by delayed gastric emptying that can lead to nausea and vomiting.
What is the corporate strategy of Evoke Pharma?
Evoke Pharma’s corporate strategy focuses on advancing the development and commercialization of Gimoti, while exploring additional pipeline opportunities within the gastrointestinal space. The company is dedicated to leveraging its expertise and partnerships to drive growth and increase shareholder value.
What is the current stock symbol for Evoke Pharma?
Evoke Pharma trades on the NASDAQ stock exchange under the ticker symbol 'EVOK'. This symbol allows investors to easily identify and trade shares of the company.
What is the importance of nasal delivery for Gimoti?
Nasal delivery allows for faster absorption into the bloodstream, resulting in quicker onset of action compared to oral medications. This method is particularly beneficial for patients who experience nausea and vomiting, as it bypasses the gastrointestinal tract, thereby enhancing tolerability and effectiveness.
What is the market potential for Gimoti?
The market potential for Gimoti is significant, given the prevalence of diabetic gastroparesis among women. With limited effective treatments available, Gimoti aims to address a substantial and underserved patient population, which could translate to a considerable commercial opportunity.
When was Evoke Pharma, Inc. founded?
Evoke Pharma was founded in 2011. Since its inception, the company has dedicated itself to addressing unmet medical needs in the field of gastrointestinal disorders through innovative drug delivery methods.
Where is Evoke Pharma, Inc. headquartered?
Evoke Pharma is headquartered in San Diego, California. This location positions the company within a thriving biotechnology and pharmaceutical ecosystem, allowing it to leverage local resources and expertise in drug development.
Who are the target patients for Gimoti?
Gimoti is specifically aimed at females suffering from diabetic gastroparesis. This condition predominantly affects women more than men, and the product seeks to improve their quality of life by providing a fast-acting treatment option.
What is the current price of Evoke Pharma, Inc. - Common Stock?
The current price of Evoke Pharma, Inc. - Common Stock is 2.230
When was Evoke Pharma, Inc. - Common Stock last traded?
The last trade of Evoke Pharma, Inc. - Common Stock was at 1:53 pm EDT on April 4th, 2025
What is the market capitalization of Evoke Pharma, Inc. - Common Stock?
The market capitalization of Evoke Pharma, Inc. - Common Stock is 7.46M
How many shares of Evoke Pharma, Inc. - Common Stock are outstanding?
Evoke Pharma, Inc. - Common Stock has 3.34M shares outstanding.